Title : Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC.

Pub. Date : 2021 Jan

PMID : 33137541






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens
2 CB839, an efficient glutaminase inhibitor, synergized with the MEK inhibitor selumetinib to enhance antitumor activity in KRAS-mutant NSCLC cells and xenografts, and the therapeutic response could be well identified by 18F-FDG PET imaging. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens